Genmab — Maj 2017

[gentogen]

Obs: DARA shows encouraging cytotoxic activity in MCL and FL cells in the presence of external effectors in vitro. In addition, DARA exerts unique and substantial effects as single agent on MCL and FL tumor cell growth

[gentogen]

DARA completely prevented the outgrowth and induced tumor regression of MCL (n=6) and FL (n=6) subcutaneous tumors

[gentogen]

In addition, the combination of DARA with Rituximab/CHOP regimen in FL, resulted in a synergistic reduction of tumor growth (n=7-10).

[gentogen]

(learningcenter.ehaweb.org)

[E_L]

I know this is very early & pre clinical, but could it have had any influence on retracting Carina at the end of March you think?

[gentogen]

Hard to tell but they must be looking at Dara combined with Ofatumumab/CHOP....

[gentogen]

https://www.ncbi.nlm.nih.gov/pubmed/22409295

[JKY_VH]

Tak gentogen.

[Bulder]

Genmab/Janssen må have haft kendskab til dette abstract, da de indstillede Carina. Det er før set, at god præklinik ikke holder i klinikken. Men det kan vel være med til at underbygge kombier med dara i NHL.

[bibob]

Tak for link gentogen. Tror Bulder har ret angående at Dara ikke er færdig i NHL. Der kan sagtens komme flere kombier som viser effekt.

[bibob]

Tak for hilsner JKY og Nickstar. Hjem til den Danske " sommer ". Frisk og solbrændt. Et forsigtigt tip inden hjemtur . 1382. Kritik modtages IKKE.

[Legolas23]

1390

[Solsen]

Janssens
har Ibrutinib til cll m.fl.skal vi huske. !

[Bulder]

Du mener, dara skal være bedre end ibrutinib, før de gider gøre noget ved det?

[Solsen]

Janssen/JNJ gør sig hele tiden nogle kommercielle overvejelser. De kan jo blot gå i gang med alt muligt andet med dara, der tilsyneladende kan have effekt i mange andre sygdomme. Ingen grund til at stjæle markedsandele fra sig selv.

[gentogen]

Updated data were presented for 80 patients with FL receiving two different administration schedules of ibrutinib and rituximab (Arm 1, 60 patients; Arm 2, 20 patients). In Arm 1 at a median time on study of 22 months, the ORR was 85%, with 35% CR. https://news.abbvie.com/news/favorable-response-rates-suggest-promise-ibrutinib-imbruvica-combination-therapy-in-two-common-types-non-hodgkins-lymphoma.htm

[gentogen]

O/CHOP. Overall response rate was 90% for the 500-mg group and 100% for the 1000-mg group. 62% of patients achieved complete response (CR)/unconfirmed CR (CRu).

[gentogen]

Ikke at jeg har forstand på det men Dara + O/CHOP kunne vel så være endnu bedre

[Bulder]

O/CHOP, er det Ofa+CHOP? Hvor er citatet fra?

[gentogen]

Fra tidligere link. 10:52 Og ja. O=Ofatumumab